Comparing the severity of second preeclampsia with first preeclampsia : a multicenter retrospective longitudinal cohort study
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved..
OBJECTIVE: Compare the clinical severity of second preeclampsia with the first preeclampsia.
METHODS: This retrospective longitudinal cohort study was conducted in three teaching hospitals in Guangzhou, where there were a total of 296 405 deliveries between 2010 and 2021. Two consecutive singleton deliveries complicated with preeclampsia were included. Clinical features, laboratory results within 1 week before delivery, and maternal and neonatal outcomes of both deliveries were collected. Univariate analyses were made using paired Wilcoxon tests and McNemar tests. Multivariable logistic regression and generalized linear models were performed to assess the association of adverse maternal and neonatal outcomes with second preeclampsia.
RESULTS: A total of 151 women were included in the study. The mean maternal age was 28 and 33 years for the first and second deliveries, respectively. The proportion of preventive acetylsalicylic acid use was 4.6% for the first delivery and 15.2% for the second delivery. No significant differences were observed in terms of blood pressure on admission, gestational weeks of admission and delivery, application of perinatal antihypertensive agents, rates of preterm delivery, and severe features between the two occurrences. However, the rates of heart disease, edema, and admission to the ICU were lower, and hospital stays were shorter in the second preeclampsia compared with the first preeclampsia. Sensitivity analysis conducted among women who did not use preventive acetylsalicylic acid yielded similar results. After adjusting for potential confounding variables, the occurrence of second preeclampsia was associated with significantly decreased risks of heart disease, edema, complications, and admission to the NICU, with odds ratios ranging between 0.157 and 0.336.
CONCLUSION: Contrary to expectations, the second preeclampsia did not exhibit worse manifestations or outcomes to the first occurrence. In fact, some clinical features and outcomes appeared to be better in the second preeclampsia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Journal of hypertension - 42(2024), 5 vom: 01. Apr., Seite 841-847 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Lizi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.04.2024 Date Revised 05.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/HJH.0000000000003642 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366556010 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366556010 | ||
| 003 | DE-627 | ||
| 005 | 20240405233335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HJH.0000000000003642 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM366556010 | ||
| 035 | |a (NLM)38164966 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Lizi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparing the severity of second preeclampsia with first preeclampsia |b a multicenter retrospective longitudinal cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: Compare the clinical severity of second preeclampsia with the first preeclampsia | ||
| 520 | |a METHODS: This retrospective longitudinal cohort study was conducted in three teaching hospitals in Guangzhou, where there were a total of 296 405 deliveries between 2010 and 2021. Two consecutive singleton deliveries complicated with preeclampsia were included. Clinical features, laboratory results within 1 week before delivery, and maternal and neonatal outcomes of both deliveries were collected. Univariate analyses were made using paired Wilcoxon tests and McNemar tests. Multivariable logistic regression and generalized linear models were performed to assess the association of adverse maternal and neonatal outcomes with second preeclampsia | ||
| 520 | |a RESULTS: A total of 151 women were included in the study. The mean maternal age was 28 and 33 years for the first and second deliveries, respectively. The proportion of preventive acetylsalicylic acid use was 4.6% for the first delivery and 15.2% for the second delivery. No significant differences were observed in terms of blood pressure on admission, gestational weeks of admission and delivery, application of perinatal antihypertensive agents, rates of preterm delivery, and severe features between the two occurrences. However, the rates of heart disease, edema, and admission to the ICU were lower, and hospital stays were shorter in the second preeclampsia compared with the first preeclampsia. Sensitivity analysis conducted among women who did not use preventive acetylsalicylic acid yielded similar results. After adjusting for potential confounding variables, the occurrence of second preeclampsia was associated with significantly decreased risks of heart disease, edema, complications, and admission to the NICU, with odds ratios ranging between 0.157 and 0.336 | ||
| 520 | |a CONCLUSION: Contrary to expectations, the second preeclampsia did not exhibit worse manifestations or outcomes to the first occurrence. In fact, some clinical features and outcomes appeared to be better in the second preeclampsia | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Bi, Shilei |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Jingjin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinghe |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Jingying |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Shifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Minglian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Weiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Manna |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jingsi |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Weitan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Junwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhijian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jianmeng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hong-Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Dunjin |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Lili |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hypertension |d 1987 |g 42(2024), 5 vom: 01. Apr., Seite 841-847 |w (DE-627)NLM01293562X |x 1473-5598 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:5 |g day:01 |g month:04 |g pages:841-847 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HJH.0000000000003642 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 5 |b 01 |c 04 |h 841-847 | ||